Product Description
Mechanisms of Action: CYP26 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Stiefel
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BT0720-201-INT | P2 |
Completed |
Psoriasis |
2007-05-01 |
|
BT0700BEL001 | P2 |
Completed |
Other |
2005-07-01 |
|
BT0700NED001 | P2 |
Completed |
Psoriasis |
2005-03-01 |